Dinoprost Tromethamine

The objective of this study was to evaluate the effect of administering 200 µg versus 100 µg of GnRH as gonadorelin hydrochloride (Factrel; Zoetis, Parsippany, NJ) at the first GnRH injection (G1) of the breeding Ovsynch in a Double-Ovsynch (DO) protocol on pregnancy per artificial insemination (P/AI) at first service in lactating dairy cows. The study was conducted across 4 commercial dairies located in California (n = 2) and Wisconsin (n = 2). We also assessed the effect of GnRH dose on ovulatory response and LH release. Each week, cows were blocked in a 2 × 2 factorial design by parity (primiparous or multiparous) and GnRH dose (100 µg or 200 µg) within each herd. The primary outcome was P/AI following estrus synchronization and timed AI. Cows were excluded if they were inseminated outside the synchronization window, culled before pregnancy diagnosis, or missed scheduled GnRH or PGF_2α treatments. Dinoprost tromethamine (12.5 mg/mL; Lutalyse HighCon, Zoetis) served as the PGF_2α source. A total of 6,621 cows met the inclusion criteria (2,525 primiparous; 4,096 multiparous). Of these, 3,310 received 100 µg GnRH (2 mL), and 3,311 received 200 µg GnRH (4 mL). A subset of 505 cows from herd A underwent transrectal ultrasonography to assess ovulatory response at G1 and 7 d later (first PGF2α of DO), with concurrent serum progesterone (P4) sampling. An additional subset of 18 cows had blood samples collected at 0 (pretreatment) and at 30, 60, 90, 120, 150, 180, 210, 240, 300, and 360 min post-treatment to measure LH concentrations. The final statistical model for P/AI included fixed effects of treatment, parity, and their interaction, with random effects of herd, service sire, herd-by-treatment-by-parity, and month fresh nested within herd-by-parity. Treatment and parity significantly affected P/AI, although their interaction was not significant. Least squares means for P/AI were higher with 200 µg than 100 µg GnRH (51.8% vs. 48.6%). When stratified, the effect in primiparous cows was minimal (52.8% vs. 51.8%), but substantial in multiparous cows (50.7% vs. 45.4%). Cows treated with 200 µg GnRH had a greater ovulatory response than those receiving 100 µg (83.0% vs. 70.8%). Parity also influenced ovulation, though no treatment-by-parity interaction was observed. When P4 was categorized (Low <3.0 ng/mL, High ≥3.0 ng/mL), a 3-way interaction emerged: in primiparous cows with Low-P4, ovulation was greater with 200 µg; in multiparous cows with High-P4, ovulation was greater with 200 µg. No treatment effect was observed on P4 concentrations 7 d post-treatment. Cows receiving 200 µg GnRH had higher peak LH and area under the curve than those receiving 100 µg, though peak timing did not differ. In summary, increasing the GnRH dose to 200 µg at G1 of the breeding Ovsynch in a DO program improved LH release, ovulatory response, and first-service P/AI, with the greatest benefit in multiparous cows.

The demethylation is suspected to play a role in the development of major depressive disorder (MDD), but the precise biological mechanisms remain unclear. Therefore, this study aimed to investigate biomarkers linked to demethylation in MDD by integrating bulk RNA sequencing (bulk RNA-seq) data and single-nucleus RNA sequencing (snRNA-seq) data.

The bulk RNA-seq data and snRNA-seq data for MDD were sourced from public databases, and the demethylation-related genes (DRGs) were extracted from the literature. Employing differential expression analysis, machine learning algorithms, and expression profiling, this study identified biomarkers. Afterward, biomarkers were incorporated into a nomogram. The study explored underlying biological mechanisms through enrichment and immune infiltration analyses, while deciphering the regulatory networks of biomarkers. Subsequent analyses included the prediction of targeted drugs, molecular docking, and the examination of the expression of these biomarkers at the single-nucleus level, followed by the identification of key cells and pseudo-time analysis of these cells. Eventually, the expression of biomarkers was clinically validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

AREG and NR4A1 were identified as biomarkers, all exhibiting down-regulated expression in MDD samples. Furthermore, the nomogram demonstrated satisfactory clinical utility for assessing MDD probability. Enrichment analysis indicated that biomarkers might affect the occurrence of MDD through "oxidative phosphorylation". Moreover, 6 types of immune infiltrating cells showed significant differences between MDD and control samples. Also, the regulatory networks were constructed, identifying the potential regulators of the biomarkers. The drugs were predicted, and the molecular docking illustrated that a robust binding interaction was found between AREG and dinoprost, with a binding energy of -84.0 kcal/mol. Additionally, snRNA-seq analysis identified 6 cell types, with excitatory neuron (EX) cells were identified as the key cells, and the expression levels of biomarkers exhibited dynamic and nonlinear changes during the differentiation of EX cells.

AREG and NR4A1, which were related to demethylation, were identified as biomarkers in MDD, providing a new perspective to understand the molecular mechanisms underlying MDD.